期刊文献+

多囊卵巢综合征控制性卵巢刺激的有效运用 被引量:5

Ovulation Induction Strategy in Polycystic Ovary Syndrome
下载PDF
导出
摘要 多囊卵巢综合征(PCOS)患病率在4%~12%,是育龄期妇女常见的涉及多系统的生殖内分泌疾病。临床表现为高雄激素、月经紊乱和不孕,代谢性障碍可表现为胰岛素抵抗、高脂血症和肥胖等。PCOS的代谢紊乱与下丘脑-垂体-卵巢-肾上腺的功能障碍有关,这些紊乱可引起长期并发症,如高血压、糖尿病和心血管疾病等,临床医生需密切监测并积极预防。PCOS促排卵治疗中,首先应使肥胖患者减轻体质量,降低体内胰岛素水平,恢复自发排卵。氯米芬为促排卵治疗的一线药物,可结合口服避孕药、二甲双胍或糖皮质激素降低体内雄激素水平以增加对氯米芬的敏感性;芳香化酶抑制剂也可用于促排卵治疗,尤其适用于既往有雌激素依赖性肿瘤的患者;促性腺激素与卵巢打孔手术可达到相同的妊娠率,临床选择时应充分考虑患者的条件及手术可能引起的并发症。体外受精中,可选择使用促性腺激素释放激素拮抗剂及激动剂诱发排卵以减少卵巢过度刺激综合征的发生,也可使用卵子体外培养以获得成功妊娠。 PCOS,with the prevalence rate 4% to 12%,is one of the most common disorder of reproductive and endocrine systems in fertile women.The principal clinical manifestations are hyperandrogenism,irregular menstruation and infertility.The metabolic dysfunction includes insulin resistance,dyslipidemia and obesity.Those metabolic disorders are involved with the dysfunction of hypothalamic pituitary ovary axis and adrenal gland.All of these disorders may contribute to the chronic complication,such as hypertension,DM,CVD.So,doctors should closely monitoring and positively prevent those metabolic disorders.Anovulation in obese women with PCOS could be successfully treated with weight loss.Clomiphene,clomiphene plus glucocorticoid,clomiphene and estrogen-progestin pretreatment,clomiphene and metformin,aromatase inhibitors,gonadotropin and ovarian surgery could be used for induction of ovulation in PCOS.GnRH antagonist and GnRH agonist could be used for PCOS during IVF to prevent OHSS.In vitro maturation of oocytes also is plausible.
出处 《国际生殖健康/计划生育杂志》 CAS 2011年第5期375-379,共5页 Journal of International Reproductive Health/Family Planning
基金 国家自然科学基金资助项目(303050768) 2009广东省教育部产学研结合项目(2008B090500194)
关键词 多囊卵巢综合征 排卵诱导 卵巢 治疗 Polycystic ovary syndrome Ovulation induction Ovary Therapy
  • 相关文献

参考文献52

  • 1Rebar R,Judd HL,Yen SS,et al.Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome[J].J Clin Invest,1976,57(5):1320-1329.
  • 2Hall JE,Taylor AE,Hayes FJ,et al.Insights into hypothalamicpituitary dysfunction in polycystic ovary syndrome[J].J Endocrinol Invest,1998,21(9):602-611.
  • 3Melrose P,Gross L.Steroid effects on the secretory modalities of gonadotropin-releasing hormone release[J].Endocrinology,1987,121(1):190-199.
  • 4Chang RJ,Laufer LR,Meldrum DR,et al.Steroid secretion in polycystic ovarian disease after ovarian suppression by a longacting gonadotropin-releasing hormone agonist[J].J Clin Endocrinol Metab,1983,56(5):897-903.
  • 5Barnes R,Rosenfield RL.The polycystic ovary syndrome:pathogenesis and treatment[J].Ann Intern Med,1989,110(5)386-399.
  • 6Burghen GA,Givens JR,Kitabchi AE.Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease[J].J Clin Endocrinol Metab,1980,50(1):113-116.
  • 7Dunaif A,Graf M.Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with the polycystic ovary syndrome[J].J Clin Invest,1989,83(1):23-29.
  • 8Flier JS,Minaker KL,Landsberg L,et al.Impaired in vivo insulin clearance in patients with severe target-cell resistance to insulin[J].Diabetes,1982,31(2):132-135.
  • 9Ciaraldi TP,el-Roeiy A,Madar Z,et al.Cellular mechanisms of insulin resistance in polycystic ovarian syndrome[J].J Clin Endocrinol Metab,1992,75(2):577-583.
  • 10Weil S,Vendola K,Zhou J,et al.Androgen and folliclestimulating hormone interactions in primate ovarian follicle development[J].Clin Endocrinol Metab,1999,84(8):2951-2956.

同被引文献61

引证文献5

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部